ES2173058T1 - Forma cristalina o de claritromicina. - Google Patents

Forma cristalina o de claritromicina.

Info

Publication number
ES2173058T1
ES2173058T1 ES97951771T ES97951771T ES2173058T1 ES 2173058 T1 ES2173058 T1 ES 2173058T1 ES 97951771 T ES97951771 T ES 97951771T ES 97951771 T ES97951771 T ES 97951771T ES 2173058 T1 ES2173058 T1 ES 2173058T1
Authority
ES
Spain
Prior art keywords
claritromycin
crystaline
methylerythromycin
solvate
isopropanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES97951771T
Other languages
English (en)
Spanish (es)
Inventor
Stephen G Spanton
Rodger F Henry
David A Riley
Jih-Hua Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25136084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2173058(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of ES2173058T1 publication Critical patent/ES2173058T1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
ES97951771T 1997-01-17 1997-12-19 Forma cristalina o de claritromicina. Pending ES2173058T1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/785,623 US5945405A (en) 1997-01-17 1997-01-17 Crystal form O of clarithromycin

Publications (1)

Publication Number Publication Date
ES2173058T1 true ES2173058T1 (es) 2002-10-16

Family

ID=25136084

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97951771T Pending ES2173058T1 (es) 1997-01-17 1997-12-19 Forma cristalina o de claritromicina.

Country Status (18)

Country Link
US (1) US5945405A (enExample)
EP (1) EP1077988A1 (enExample)
JP (3) JP4058114B2 (enExample)
KR (1) KR100567149B1 (enExample)
CN (1) CN1174991C (enExample)
AR (3) AR011077A1 (enExample)
AU (1) AU735598B2 (enExample)
BR (1) BR9714287A (enExample)
CA (4) CA2387356C (enExample)
CZ (1) CZ297433B6 (enExample)
DE (1) DE97951771T1 (enExample)
ES (1) ES2173058T1 (enExample)
IL (1) IL130255A0 (enExample)
NZ (1) NZ336073A (enExample)
TR (1) TR199901578T2 (enExample)
TW (1) TW574224B (enExample)
WO (1) WO1998031699A1 (enExample)
ZA (1) ZA98116B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
GB9827355D0 (en) * 1998-12-11 1999-02-03 Biochemie Sa Organic compounds
KR100322313B1 (ko) * 1999-10-21 2002-02-06 민경윤 클라리스로마이신 결정형 2의 제조방법 및 이에 사용되는 클라리스로마이신 포르메이트
US6627743B1 (en) 1999-12-03 2003-09-30 Abbott Laboratories 6-O-methylerythromycin A crystal form III
CN1666991A (zh) * 1999-12-16 2005-09-14 特瓦制药工业有限公司 克拉霉素多晶型物的制备方法和新的多晶型物ⅳ
FR2802534B1 (fr) * 1999-12-20 2002-02-01 Merial Sas Procede pour preparer et isoler la 9-deoxo-9 (z)- hydroxyiminoerythromycine a
CN1450903A (zh) 2000-01-11 2003-10-22 特瓦制药工业有限公司 克拉霉素多晶型物的制备方法
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
CA2401571A1 (en) * 2000-02-29 2001-09-07 Ilya Avrutov Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
DE60122791T2 (de) * 2000-03-15 2007-10-04 Hanmi Pharm. Co., Ltd. Verfahren zur Herstellung von Clarythromycin mit nicht pharmazeutischer Qualität
KR100367981B1 (ko) * 2000-11-23 2003-01-14 한미약품공업 주식회사 클라리스로마이신 결정형 2의 제조 방법 및 이 방법에사용되는 결정성 클라리스로마이신 메실레이트 삼수화물
AU6381201A (en) * 2000-03-28 2001-10-08 Biochemie Gmbh Granulated particles with masked taste
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
ATE485837T1 (de) * 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
KR100408848B1 (ko) * 2001-03-12 2003-12-06 주식회사 씨트리 클래리스로마이신의 정제방법
RU2217160C2 (ru) * 2001-04-20 2003-11-27 Челябинская государственная медицинская академия Способ местного лечения урогенитального хламидиоза у женщин
JP2004537566A (ja) * 2001-08-01 2004-12-16 ブリストル−マイヤーズ　スクイブ　カンパニー 味マスキング組成物
TW200302830A (en) * 2002-01-11 2003-08-16 Chugai Pharmaceutical Co Ltd Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate
CN100427498C (zh) * 2003-03-02 2008-10-22 王凌峰 克拉霉素a型结晶
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
EP1648415A4 (en) 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
CA2535398C (en) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004273830B2 (en) 2003-09-15 2011-03-24 Shionogi, Inc. Antibiotic product, use and formulation thereof
PL1670433T3 (pl) 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
EP1771158A4 (en) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSE DISTRIBUTION
US20060111560A1 (en) * 2004-11-01 2006-05-25 Glenmark Pharmaceuticals Limited Process for the preparation of crystalline form II of clarithromycin
US8067399B2 (en) * 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
CA2614412A1 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
WO2007036951A2 (en) * 2005-08-31 2007-04-05 Alembic Limited Process to obtain 6-o-methylerythromycin a (clarithromycin)_form ii
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
CN101426475A (zh) 2006-04-21 2009-05-06 安塔雷斯制药Ipl股份公司 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
DE102007016367A1 (de) 2007-04-03 2008-10-09 Grünenthal GmbH Polymorph von Clarithromycin (Form V)
WO2009023191A2 (en) * 2007-08-09 2009-02-19 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of clarithromycin
EP2030613A1 (en) 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
US9119769B2 (en) 2011-12-30 2015-09-01 The Curators Of The University Of Missouri Method for transforming pharmaceutical crystal forms
CN103087130B (zh) * 2013-02-06 2015-12-23 浙江国邦药业有限公司 一种克拉霉素晶型转换方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5782400A (en) 1980-11-12 1982-05-22 Taisho Pharmaceut Co Ltd Erythromycin derivative
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
JPH0755958B2 (ja) * 1986-10-03 1995-06-14 大正製薬株式会社 エリスロマイシンａ誘導体の製造方法
KR960000434B1 (ko) * 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
JP2526951B2 (ja) * 1986-12-17 1996-08-21 大正製薬株式会社 エリスロマイシンａ誘導体およびその製造方法
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
JP2751385B2 (ja) * 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンａオキシム及びその塩の製造方法
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
CA2261732C (en) * 1996-07-29 2001-07-24 Abbott Laboratories Preparation of crystal form ii of clarithromycin
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin

Also Published As

Publication number Publication date
CZ297433B6 (cs) 2006-12-13
JP2004075689A (ja) 2004-03-11
AU735598B2 (en) 2001-07-12
US5945405A (en) 1999-08-31
BR9714287A (pt) 2000-04-18
AU5532698A (en) 1998-08-07
CN1244869A (zh) 2000-02-16
JP2000509725A (ja) 2000-08-02
AR039666A2 (es) 2005-03-02
DE97951771T1 (de) 2004-07-08
CA2387361A1 (en) 1998-07-23
CA2387356C (en) 2003-05-27
CA2419499A1 (en) 1998-07-23
WO1998031699A1 (en) 1998-07-23
EP1077988A1 (en) 2001-02-28
CA2277274C (en) 2003-05-27
AR011077A1 (es) 2000-08-02
CN1174991C (zh) 2004-11-10
KR100567149B1 (ko) 2006-04-04
NZ336073A (en) 2001-01-26
TW574224B (en) 2004-02-01
CA2277274A1 (en) 1998-07-23
KR20000070220A (ko) 2000-11-25
JP5190350B2 (ja) 2013-04-24
JP2009137975A (ja) 2009-06-25
CA2387361C (en) 2003-05-27
IL130255A0 (en) 2000-06-01
AR039667A2 (es) 2005-03-02
CA2387356A1 (en) 1998-07-23
ZA98116B (en) 1998-07-08
TR199901578T2 (xx) 1999-09-21
CZ242699A3 (cs) 1999-11-17
JP4058114B2 (ja) 2008-03-05

Similar Documents

Publication Publication Date Title
ES2173058T1 (es) Forma cristalina o de claritromicina.
RU93050129A (ru) Новые производные эритромицина, метод их получения и фармацевтическая композиция на их основе и промежуточные соединения синтеза
FI954979A7 (fi) Kemoherkistävinä aineina käytettävät 10,11-metanodibentsosuberaanijohdannaiset
CO4650278A1 (es) Procedimiento y formas cristalinas de 2-metil-tieno-benzo- diacepina
NO982872D0 (no) Forbindelser med veksthormonfrigj°rende egenskaper
YU11997A (sh) Laktamski derivati i njihove farmaceutske kompozicije
ITGE930012A0 (it) Cannula laparoscopica.
ES2195970T3 (es) L-ribavirina y usos de la misma.
BR9914221A (pt) Derivados de glicopeptìdeos e composições farmacêuticas contendo os mesmos
CA2386828A1 (en) Novel pseudoerythromycin derivatives
DE69315503D1 (de) Aufblaseinrichtung für Gaskissen mit inhibierten, gaserzeugenden Zusammensetzungen
ES2138993T3 (es) Halicondrinas: macrolidos de polieter citotoxicos.
FI980862A7 (fi) Kiraalisia metyylifenyylioksatsolidinoneja
DE69527696D1 (de) Kristalline Paclitaxel Hydrate
DE69300541D1 (de) Wasserhaltige Lauge.
ATE214698T1 (de) Neue carbamazepin hapten analoge
FR2701943B1 (fr) Purification du pentafluoroéthane.
FI931826L (fi) Foerfarande foer framstaellning av en virussaeker, hoegt renad faktor viii
FI943358A7 (fi) 16-rengasatomisten makrolidiantibioottien amidijohdannaisia
MD1788F2 (en) Erythromycin A 9-O-oximes derivatives, pharmaceutical composition on base thereof and method of treatment of infectious diseases
FI930801L (fi) Foerfarande foer behandling av den flora, som kontaminerar pappersbakteriernas vattenomlopp, medelst bakterier
YU48915B (sh) Sulfonilkarbamid i postupak za njegovo dobijanje
ES2181790T3 (es) Compuestos azaciclohexapeptidicos.
DE69406441D1 (de) Syntetische aglukodalbaheptid-antibiotika
DE69108930D1 (de) Aus dalbaheptide hergestellte tetrapeptidantibiotika.